Canakinumab for Atherosclerotic Disease

Referido pela AMICOR Maria Inês Reinert Azambuja

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M Ridker, M.D., et al.

August 27, 2017DOI: 10.1056/NEJMoa1707914

Share:

Abstract

Article

References

Citing Articles (1)

Comments

Metrics

BACKGROUND

Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.

+++++++++++++++

CONCLUSIONS

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)